An Observational Study of Sthaulya Inconcern with Obesity

Obesity, as considered, is the most common nutritional based disorder in all affluent societies. WHO 2010 report, considering the same, worldwide obesity seem too had doubled since 1980. 65% of the world's population lives in countries where overweight & obesity both does kill more people although being underweight. So obesity is gaining absolutely more attention at the global zone. That seems to be the reason for which many countries are absolutely making an effort to find perfect remedy for this ascending problem. The incidence of Diabetes mellitus, hypertension, angina pectoris and myocardial infarction. Etc. is with the raising source among obese individuals. Commonly, it seems that the obesity is due to excessive eating and lack of adequate exercise. Hence this topic is selected for research. Objectives: This study is conducted with the objectives to evaluate that, how the lifestyle modification does affect overweight and obesity both. Material and Methods: An attempt has been made in the present study that the 30 patients of Sthaulya have been selected between the age group 18 years to 50 years. Observations were well noted. Data collected from the patients was tabulated under following two sections, General observations like age, sex, marital status, diet and lifestyle etc. Results: Statistical analysis was thorough resulting the illustrations alike; if people do habituate with the following type of lifestyle, but obviously, they may obese themselves, in case of Mind related causative factors. There are majority of the patients alike 80% were habituated with Happiness and only 20% were carrying lack of stress. Hence, we had mentioned that if in case the people are habituated with the same i.e., happiness, but obviously they will turn up obese. Conclusion: Sthaulya is the main over nutritive disorder which further causes other complications if not cured properly

Antiepileptic Activity of Unmadgajakesari – A Herbomineral Formulation: An Experimental Evaluation

Epilepsy is the most common chronic neurological disorder characterized by episodes of recurrent unprovoked seizures Unmadgajakesari(UGK) is a herbomineral formulation claimed to be useful in epilepsy in traditional medicine. Lack of scientific evidence of  UGK for its use in epilepsy lead to the objective of the present work. To evaluate the antiepileptic activity of Unmadgajakesari in animal models After doing the acute toxicity study of  UGK, it was evaluated for its antiepileptic activity in Maximal Electroshock(MES) and Pentylenetetrazole(PTZ) induced seizures models in albino wistar rats. For each study animals were divided into 6 groups, each group comprising of 6 animals . Group I –Normal control, Group II-Vehicle control(ghrita), Group III- Drug control(positive control). In test groups(IV-VI) UGK was administered in doses of  70, 140 and 280mg/kg  orally for 8days. Antiepileptic activity was evaluated  on day 1and 8.UGK was found to be nontoxic upto dose of 2000mg/kg. Significant antiepileptic activity was observed in both the groups on 8th day of UGK  administration. In the MES model, significant abolition of tonic hind limb extension was observed in dose of 280mg/kg. In PTZ model, UGK was most effective in the dose of 70mg/kg in delaying the onset and  reducing  the severity of clonic convulsions. No adverse effects or mortality was seen in this study.UGK appears to  have significant antiepileptic activity after repeated administration. With wide spectrum of action, this drug may be useful addition to antiepileptic agents

Comparative study on efficacy of empagliflozin versus sitagliptin, as an add-on therapy to metformin in type 2 diabetic patients

Introduction: More than 28.7 million individuals throughout the globe suffer from diabetes mellitus, with an estimated 11 percent of the population living with the condition in India. Changes in lifestyle and a variety of treatment plans are used in management. Metformin is a key drug for glycemic control, both when used alone and in combination. Our research compares the effectiveness of glycemic control achieved by empagliflozin plus sitagliptin. Methods: This study took place from November 2022 to April 2023 at the tertiary care hospital. The study did not begin until the ethical review was completed. There were two groups of patients, A and B. Everyone received a daily dose of Metformin 1,000 milligrams. Sitagliptin (50 mg twice daily) was administered to individuals in Group A, whereas Empagliflozin (10 mg once daily) was given to those in Group B. After three months of therapy, HbA1c was used to compare the two groups' levels of glycemic control to those at the start of treatment. To do this, we employed a proforma. Version 25 of the Statistical Package for the Social Sciences (SPSS Inc., Chicago, USA) was used for the analysis. Results: The average age of the 300 patients that participated in the trial was 42.33. There were 57.67% men and 42.33% females. “The mean reduction in HbA1c from baseline in Group A was −0.65 ± 0.11% and in Group B was −1.34 ± 0.13% with statistically significant P-value (P-value = 0.000).” Conclusion: The combination of Empagliflozin and Metformin is superior to that of Sitagliptin and Metformin for the maintenance of glycemic control